Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
The spread of a malignant neoplasm to the lymph nodes.
Biomarker and diagnostic research for metastatic malignant neoplasm in the lymph nodes has been reported in the published literature.
6 clinical trials registered, 1 recruiting. Interventions under study include other interventions, procedural interventions, drug therapy, and biologic therapy. Pipeline includes 1 PHASE3, 2 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07018505](https://clinicaltrials.gov/study/NCT07018505) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:50 AM UTC
EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph Node Metastasis Status in Breast Cancers |
— |
Yunnan Cancer Hospital |
NOT_YET_RECRUITING |
[NCT07154563](https://clinicaltrials.gov/study/NCT07154563) | Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer | — | Yunnan Cancer Hospital | RECRUITING |
[NCT03793166](https://clinicaltrials.gov/study/NCT03793166) | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | PHASE3 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
[NCT04071236](https://clinicaltrials.gov/study/NCT04071236) | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | PHASE1 | National Cancer Institute (NCI) | UNKNOWN |
[NCT03796767](https://clinicaltrials.gov/study/NCT03796767) | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer | PHASE2 | University of Utah | UNKNOWN |
218 publications have been identified in PubMed for metastatic malignant neoplasm in the lymph nodes. Kisho has analyzed 128 by research type. Research spans Basic Science / Preclinical (33%), Review / Meta-Analysis (23%), and Diagnostic / Biomarker (19%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 42 | 33% |
Research summaries | 30 | 23% |
Testing and diagnosis research | 24 | 19% |
Disease patterns and progression | 12 | 9% |
Clinical study results | 8 | 6% |
Other research | 6 | 5% |
Patient case studies | 4 | 3% |
New treatment approaches | 2 | 2% |
Zhou Y (2026). [PMID: 41139164](https://pubmed.ncbi.nlm.nih.gov/41139164/). *Br J Cancer*. [Diagnostic / Biomarker]
Omami G (2026). [PMID: 41107092](https://pubmed.ncbi.nlm.nih.gov/41107092/). *Oral Maxillofac Surg Clin North Am*. [Review / Meta-Analysis]
Fernandes MC (2026). [PMID: 40853592](https://pubmed.ncbi.nlm.nih.gov/40853592/). *Eur Radiol*. [Diagnostic / Biomarker]
Sun X (2026). [PMID: 41528023](https://pubmed.ncbi.nlm.nih.gov/41528023/). *Surg Laparosc Endosc Percutan Tech*. [Basic Science / Preclinical]
Li F (2026). [PMID: 40489753](https://pubmed.ncbi.nlm.nih.gov/40489753/). *Hepatology*. [Epidemiology / Natural History]
Deng Y (2026). [PMID: 41557810](https://pubmed.ncbi.nlm.nih.gov/41557810/). *Proc Natl Acad Sci U S A*. [Diagnostic / Biomarker]
Cai Y (2026). [PMID: 41538100](https://pubmed.ncbi.nlm.nih.gov/41538100/). *Clin Oral Investig*. [Epidemiology / Natural History]
Karakousi T (2026). [PMID: 41576931](https://pubmed.ncbi.nlm.nih.gov/41576931/). *Cancer Cell*. [Basic Science / Preclinical]
Yuan J (2026). [PMID: 41404890](https://pubmed.ncbi.nlm.nih.gov/41404890/). *Chin Med J (Engl)*. [Review / Meta-Analysis]
Lou KL (2026). [PMID: 41712645](https://pubmed.ncbi.nlm.nih.gov/41712645/). *Proc Natl Acad Sci U S A*. [Diagnostic / Biomarker]